“Occurring in nature” in S. 3(c) only qualifies the nearest reasonable referent “non-living substance”: Madras HC directs patent protection for antibody invention
“The real challenge with a patent application in respect of a synthesized non-living substance is establishing novelty, technical advance and not patent eligibility”